Neighbourly Pharmacy Inc.
TSX:NBLY.TO
18.6 (CAD) • At close March 21, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) CAD.
| 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 Q3 | 2022 Q2 | 2022 Q1 | 2021 Q4 | 2021 Q3 | 2021 Q2 | 2021 Q1 | 2020 Q4 | 2020 Q3 | 2020 Q2 | 2020 Q1 | 2019 Q4 | 2019 Q3 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 283.958 | 203.2 | 196.842 | 190.612 | 265.286 | 178.875 | 114.376 | 112.317 | 139.18 | 90.668 | 85.345 | 83.273 | 109.371 | 58.856 | 54.994 | 52.771 | 58.228 |
| Cost of Revenue
| 170.61 | 122.444 | 120.343 | 114.161 | 161.742 | 108.506 | 72.011 | 70.396 | 88.475 | 57.029 | 53.137 | 52.06 | 68.882 | 37.068 | 33.768 | 33.648 | 35.321 |
| Gross Profit
| 113.348 | 80.756 | 76.499 | 76.451 | 103.544 | 70.369 | 42.365 | 41.921 | 50.705 | 33.639 | 32.208 | 31.213 | 40.489 | 21.788 | 21.226 | 19.123 | 22.907 |
| Gross Profit Ratio
| 0.399 | 0.397 | 0.389 | 0.401 | 0.39 | 0.393 | 0.37 | 0.373 | 0.364 | 0.371 | 0.377 | 0.375 | 0.37 | 0.37 | 0.386 | 0.362 | 0.393 |
| Reseach & Development Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| General & Administrative Expenses
| 85.254 | 61.932 | 59.41 | 57.762 | 76.786 | 51.758 | 32.079 | 31.739 | 37.702 | 25.252 | 22.672 | 22.303 | 27.573 | 15.252 | 14.69 | 15.099 | 15.705 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 85.254 | 61.932 | 59.41 | 57.762 | 76.786 | 51.758 | 32.079 | 31.739 | 37.702 | 25.252 | 22.672 | 22.303 | 27.573 | 15.252 | 14.69 | 15.099 | 15.705 |
| Other Expenses
| 0 | 0 | -6.728 | -2.157 | 2.568 | 0.037 | 6.889 | 7.199 | 7.996 | 5.414 | -67.228 | 37.934 | -110.855 | -3.698 | -3.786 | -4.671 | -4.995 |
| Operating Expenses
| 106.769 | 77.903 | 75.257 | 73.998 | 104.184 | 61.072 | 38.968 | 38.938 | 45.698 | 30.666 | 27.417 | 28.086 | 33.303 | 19.047 | 18.5 | 19.025 | 19.841 |
| Operating Income
| 2.96 | 1.321 | -0.636 | -1.611 | -4.077 | -1.7 | 2.284 | 0.108 | 2.863 | -0.617 | -13.561 | -0.102 | 4.72 | 1.497 | 2.368 | -1.174 | 0.853 |
| Operating Income Ratio
| 0.01 | 0.007 | -0.003 | -0.008 | -0.015 | -0.01 | 0.02 | 0.001 | 0.021 | -0.007 | -0.159 | -0.001 | 0.043 | 0.025 | 0.043 | -0.022 | 0.015 |
| Total Other Income Expenses Net
| -0.392 | -7.242 | -8.606 | -6.221 | -0.869 | -2.257 | -1.113 | -2.875 | -2.144 | -3.59 | -75.224 | 34.705 | -113.321 | -4.942 | -4.144 | -5.943 | -7.208 |
| Income Before Tax
| -5.024 | -12.578 | -14.743 | -12.124 | -10.525 | 3.517 | -0.231 | -2.348 | 0.211 | -2.62 | -73.682 | 32.044 | -111.198 | -3.812 | -4.96 | -8.083 | -8.308 |
| Income Before Tax Ratio
| -0.018 | -0.062 | -0.075 | -0.064 | -0.04 | 0.02 | -0.002 | -0.021 | 0.002 | -0.029 | -0.863 | 0.385 | -1.017 | -0.065 | -0.09 | -0.153 | -0.143 |
| Income Tax Expense
| -0.482 | -2.361 | -2.738 | -6.547 | -1.911 | 3.383 | 0.512 | -10.934 | 0.863 | 0.774 | 3.254 | 1.775 | 0.756 | 0.06 | 0.358 | 0.148 | 0.153 |
| Net Income
| -4.827 | -10.453 | -12.113 | -5.31 | -8.975 | -0.216 | -0.999 | 8.31 | -0.889 | -3.651 | -77.128 | 29.926 | -112.426 | -3.872 | -4.96 | -8.231 | -8.461 |
| Net Income Ratio
| -0.017 | -0.051 | -0.062 | -0.028 | -0.034 | -0.001 | -0.009 | 0.074 | -0.006 | -0.04 | -0.904 | 0.359 | -1.028 | -0.066 | -0.09 | -0.156 | -0.145 |
| EPS
| -0.11 | -0.23 | -0.27 | -0.12 | -0.2 | -0.005 | -0.029 | 0.24 | -0.026 | -0.11 | -7.5 | 2.91 | -3.36 | -0.12 | -0.15 | -0.25 | -0.25 |
| EPS Diluted
| -0.11 | -0.23 | -0.27 | -0.12 | -0.2 | -0.005 | -0.029 | 0.24 | -0.026 | -0.11 | -7.5 | 2.91 | -3.36 | -0.12 | -0.15 | -0.25 | -0.25 |
| EBITDA
| 28.105 | 18.832 | 10.369 | 22.753 | 29.334 | 19.353 | 10.294 | 10.191 | 13.012 | 8.392 | -57.686 | 46.733 | -97.885 | 3.468 | 2.756 | -0.612 | 2.229 |
| EBITDA Ratio
| 0.099 | 0.093 | 0.053 | 0.119 | 0.111 | 0.108 | 0.09 | 0.091 | 0.093 | 0.093 | -0.676 | 0.561 | -0.895 | 0.059 | 0.05 | -0.012 | 0.038 |